Anti-ganglioside GD3 (monoclonal antibody)

CATALOG # 1977
Amount 50 µl
Price $375.00
Qty
 
Anti-ganglioside GD3 (monoclonal antibody)
  • Catalog #:1977
  • Scientific Name:Anti-ganglioside GD3 (monoclonal antibody)
  • Common Name:R-24 Antibody; Monoclonal,isotype IgG/IgM
  • SDSView Safety Data Sheet
  • Data Sheet:View Data Sheet
  • Formula Weight:n/a
  • Unit:50 µl
  • Source:mouse
  • Purity:supernatant. not purified
  • Analytical Methods:TLC Immunoblotting; ELISA
  • Natural Source:mouse R-24 cell
  • Solubility:water
  • Physical Appearance:liquid
  • Storage:-20°C
  • Dry Ice:Yes
  • Hazardous:Yes
  • Literature References:Application Notes:

    Anti-Ganglioside-GD3 (anti-GD3) is very useful in the identification of GD3 and in immunotargeting cells expressing GD3. GD3 is predominantly expressed during neuronal development and its expression becomes very limited in adult tissues. GD3 expression is unusually high in basal cell carcinomas and malignant melanomas and is thought to be a human melanomaspecific antigen.3 Although GD3 is not immunogenic it has been investigated as a tool for immunotargeting human melanoma cells with anti-GD3.4 Over expression of GD3 has led to apoptosis by recruiting mitochondria to apoptotic pathways and suppressing NF-B activation and subsequent B-dependent gene induction. Increased levels of GD3 have also been found to be associated with proliferative diseases, such as atherosclerosis.

    References:
    1. H. Yoshino, et al. “Fucosyl-GM1 in Human Sensory Nervous Tissue Is a Target Antigen in Patients with Autoimmune Neuropathies” Journal of Neurochemistty, Vol. 61 pp. 658, 1993
    2. S. Kusunoki, et al. “Neuropathy and IgM paraproteinemia: Differential binding of IgM M-proteins to peripheral nerve glycolipids” Neurology, Vol. 37 pp. 1795, 1987
    3. L. Pierre et al. “Anti-GD3 Monoclonal Antibody Effects on Lymphocytes and Antibody-Dependent Cellular Cytotoxicity” Cancer Biotherapy & Radiopharmaceuticals, Vol. 21(6) pp. 553-560, 2007
    4. A. Lo et al. “Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors” Clinical Cancer Research, Vol. 16(10) pp. 2769-2780, 2010